Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams S.; Schmid P.; Rugo H. S.; Winer E. P.; Loirat D.; Awada A.; Cescon D. W.; Iwata H.; Campone M.; Nanda R.; Hui R.; Curigliano G.; Toppmeyer D.; OShaughnessy J.; Loi S.; Paluch-Shimon S.; Tan A. R.; Card D.; Zhao J.; Karantza V.; Cortes J.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

【24h】

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

机译：Pembrolizumab单药治疗以前治疗的转移性三重阴性乳腺癌：COHORT A II期主题 - 086研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC.

机译：None

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2019年第3期|共8页
作者
Adams S.; Schmid P.; Rugo H. S.; Winer E. P.; Loirat D.; Awada A.; Cescon D. W.; Iwata H.; Campone M.; Nanda R.; Hui R.; Curigliano G.; Toppmeyer D.; OShaughnessy J.; Loi S.; Paluch-Shimon S.; Tan A. R.; Card D.; Zhao J.; Karantza V.; Cortes J.;
展开▼
作者单位

NYU Sch Med Dept Med Perlmutter Canc Ctr 160 East 34th St 4th Floor New York NY 10016 USA;

Queen Mary Univ London Barts Canc Inst Ctr Expt Canc Med London England;

Univ Calif San Francisco Dept Med Helen Diller Family Comprehens Canc Ctr San Francisco CA USA;

Dana Farber Canc Inst Med Oncol Boston MA 02115 USA;

Inst Curie Paris France;

Univ Libre Bruxelles Inst Jules Bordet Dept Med Oncol Brussels Belgium;

Univ Toronto Princess Margaret Canc Ctr Toronto ON Canada;

Aichi Canc Ctr Hosp Nagoya Aichi Japan;

Inst Cancerol Ouest Nantes France;

Univ Chicago Dept Med Sect Hematol Oncol 5841 S Maryland Ave Chicago IL 60637 USA;

Westmead Hosp Sydney NSW Australia;

Univ Milan Dept Oncol &

Hematol Milan Italy;

Rutgers Canc Inst New Jersey Med Oncol New Brunswick NJ USA;

Baylor Univ Med Ctr Dallas TX USA;

Peter MacCallum Canc Ctr Div Res &

Canc Med Melbourne Vic Australia;

Sheba Med Ctr Breast Canc Serv Young Women Ramat Gan Israel;

Atrium Hlth Levine Canc Inst Charlotte NC USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Vall dHebron Inst Oncol Breast Canc Program Barcelona Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
anti-PD-1; immunotherapy; pembrolizumab; triple-negative breast neoplasms;

机译：抗PD-1;免疫疗法;Pembrozumab;三阴性乳房肿瘤;

相似文献

外文文献
中文文献
专利

1. Anlotinib has good efficacy and low toxicity: a phase Ⅱ study of anlotinib in pre-treated HER-2 negative metastatic breast cancer [J] . Nanlin Hu, Jiayu Wang, Yang Luo, 癌症生物学与医学（英文版） . 2021,第003期
2. Anlotinib has good efficacy and low toxicity: a phase Ⅱ study of anlotinib in pre-treated HER-2 negative metastatic breast cancer [J] . Nanlin Hu, Yiran Si, Jian Yue, 癌症生物学与医学：英文版 . 2021,第003期
3. Phase III study of TAC and TP regimens as neoadjuvant chemotherapy in patients with triple-negative breast cancer [J] . Hanguang Ruan, Juan Xiong, Meng Wu 中德临床肿瘤学杂志（英文版） . 2014,第007期
4. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study [J] . Adams S., Loi S., Toppmeyer D., Annals of oncology: official journal of the European Society for Medical Oncology . 2019,第3期

机译：Pembrolizumab单疗法以前未经治疗，PD-L1阳性，转移性三重阴性乳腺癌：COHORT B期间Keynote-086研究
5. CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2-metastatic breast cancer (MBC) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Contessa Trio：跨国，多中心，第2期替补患者3种不同的PD-（L）1抑制剂在转移性三阴性乳腺癌（TNBC）和老年人患者中患者的胸膜肺癌（MBC）
6. A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：HER-阳性/ HER2阴性转移性乳腺癌患者Pembolizumab和Eribulin的II期研究（Kelly Study）
7. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
8. A Study of Erlotinib Monotherapy and in Combination with Pembrolizumab in Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer [D] . Liu, Qiong. 2021

机译：Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
9. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer [O] . Steven J. Isakoff, Erica L. Mayer, Lei He, -1

机译：TBCRC009：铂单药治疗与生物标志物评估在转移性三阴性乳腺癌中的多中心II期临床试验
10. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study [O] . S. Adams, S. Loi, D. Toppmeyer, 2019

机译：Pembrolizumab单疗法以前未经治疗，PD-L1阳性，转移性三重阴性乳腺癌：COHORT B的II期考试-086研究
11. Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide- Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy; Annual rept. 27 Apr 2007-26 Apr 2008 [R] . Disis, M. L. 2008

机译：对接受曲妥珠单抗单一疗法的IIIB和IV期HER2阳性乳腺癌患者施用HER-2 / neu（HER2）细胞内结构域（ICD）基于肽的疫苗的II期研究;年度报告。 2007年4月27日至2008年4月26日

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

摘要

著录项

相似文献

相关主题

期刊订阅